ASPIRINE ET CANCER

A. M. Algra& P. M. Rothwell, « Effects of regular aspirin on long-term cancer incidence and metastasis : a systematic comparison of evidence from observational studies versus randomised trials », in Lancet Oncol., vol. 13, n^o 5, pp. 518-527, 2012

J. Burn et al., « Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer : an analysis from the CAPP2 randomised controlled trial », in Lancet, n^o 378, pp. 2081-2087, 2011

A. T. Chan& N. R. Cook, « Are we ready to recommend aspirin for cancer prevention ? », in Lancet, n^o 379, pp. 1569-1571, 2012

B. F. Cole et al., « Aspirin for the chemoprevention of colorectal adenomas : meta-analysis of the randomized trials », in J Natl Cancer Inst., vol. 101, pp. 256-266, 2009

P. M. Rothwell et al., « Long-term effect of aspirin on colorectal cancer incidence and mortality : 20-year follow-up of five randomised trials », in Lancet,n^o 376, pp. 1741-1750, 2010 ; « Effect of daily aspirin on long-term risk of death due to cancer : analysis of individual patient data from randomised trials », in Lancet,n^o 377, pp. 31-41, 2011 ; « Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death : analysis of the time course of risks and benefits in 51 randomised controlled trials », in Lancet,n^o 379, pp. 1602-1612, 2012 ; « Effect of daily aspirin on risk of cancer metastasis : a study of incident cancers during randomised controlled trials », in Lancet, n^o 379, pp. 1591-1601, 2012.